Kornimate/medical-research-clean huggingface dataset:
assessment of left atrial appendage morphology in patients after ischemic stroke

Conditions: Ischemic Stroke

Summary: stroke remains the most dangerous and frightening complication of atrial fibrillation (af). numerous factors predisposing to peripheral embolism in patients with af have been well defined, documented and included in the cha2ds2vasc score. although proper anticoagulation minimizes the risk attributable to "known" risk factors, stroke may still occur. thus, "unknown" risk factors may play an important role in stroke risk stratification in patients with af. the investigators assume that one of the important "unknown" risk factor is left atrial appendage (laa) morphology. the assam study is planned to include 100 patients after ischemic stroke or transient ischemic attack (tia) and known status of anticoagulation at the time of stroke. the control group will consist of 100 patients scheduled for af ablation without a history of stroke or tia.


Eligibility criteria:
inclusion criteria: * history of ischemic stroke or transient ischemic attack * history of af/al * known status of anticoagulation at the time of stroke (treatment dose, inr level) exclusion criteria: * hemorrhagic stroke * serious renal impairment with gfr \<30 ml/min * hyperthyroidism * allergy to the contrast agent * mental inability to sign the informed consent * receptive aphasia
deep learning model for the prediction of post-lt hcc recurrence

Conditions: Liver Transplant Disorder; Liver Cancer; Recurrent Cancer

Summary: identifying patients at high risk for recurrence of hepatocellular carcinoma (hcc) after liver transplantation (lt) represents a challenging issue. the present study aims to develop and validate an accurate post-lt recurrence prediction calculator using the machine learning method.

in 1996, the introduction of the milan criteria (mc) strongly modified the selection process of hepatocellular cancer (hcc) patients waiting for liver transplantation (lt). many attempts to widen mc have been proposed. initially, exclusively morphology-based (nodules number and target lesion diameter) criteria were created. in the last years, extended criteria also based on biological parameters have been added. among the most adopted biology-based features, the levels of different tumor markers, liver function parameters like the model for end-stage liver disease (meld), the radiological response after neo-adjuvant therapies, and the length of waiting-time (wt) can be reported. unfortunately, all the proposed models showed suboptimal prediction abilities for the risk of post-lt recurrence. such impairment was derived from the limitations of the standard statistical methods to account for many variables and their non-linear interactions. therefore, developing a model based on artificial intelligence (ai) represents an attractive way to improve prediction ability. thus, the investigators hypothesize that an ai model focused on an accurate post-transplant hcc recurrence prediction should improve our ability to pre-operatively identify patients with different classes of risk for hcc recurrence after transplant. this study aims to develop an ai-derived prediction model combining morphology and biology variables. a training set derived from an international cohort was adopted for doing this. a test set derived from the same international cohort and a validation cohort were adopted for the internal and external validation, respectively. a user-friendly web calculator was also developed.

Eligibility criteria:
inclusion criteria: * consecutive adult (≥18 years) patients enlisted and transplanted with the primary diagnosis of hcc during the period 2000-2018. exclusion criteria: * patients with hcc diagnosed only at pathological examination (incidental hcc) * patients with mixed hepatocellular-cholangiocellular cancer misdiagnosed as hcc * patients with cholangiocellular cancer misdiagnosed as hcc * patients dying early after lt (≤ one month)

Keywords: artificial intelligence deep learning mathematical model
treatment of reperfusion event by vitamin c infusion

Conditions: Angina Pectoris

Summary: primary hypothesis: prophylactic vitamin c intravenous infusion at the time of percutaneous coronary intervention (pci) would limit the size of the infarct, assessed by measurements of cardiac biomarkers, during acute myocardial infarction. secondary hypotheses: prophylactic vitamin c intravenous infusion at the time of percutaneous coronary intervention (pci) would limit the size of the infarct, as measured by the area of delayed hyperenhancement that was seen on cardiac magnetic resonance imaging (mri), assessed on day 5 after infarction, during acute myocardial infarction.

this is a multicenter, prospective, controlled, randomized study that will be conducted at up to 5 centers in italy. all patients who meet the eligibility criteria will be randomized to receive during surgical procedure an intravenous infusion of vitamin c or placebo. patients will have repeat clinical follow-up to 5 days, 3 and 6 months and 1 year. the new angiography evaluation will be done if necessary. the study population will consist of at least 100 patients who presented within 12 hours after the onset of chest pain, who had st-segment elevation of more than 0.1 mv in two contiguous leads, and for whom the clinical decision was made to treat with percutaneous coronary intervention (pci). following confirmation of eligibility criteria, patients will be randomized in a 1:1 ratio to receive prophylactic infusion of vitamin c or placebo. the coronary angiograms will be assessed at a core laboratory with quantitative coronary angiography. the incidence of clinical events, including death, myocardial infarction, target vessel revascularization, stent thrombosis, will be evaluated at 1, 3, 6 and, 12 months.

Eligibility criteria:
inclusion criteria: * subjects who presented within 12 hours after the onset of chest pain, who had st-segment elevation of more than 0.1 mv in two contiguous leads, and for whom the clinical decision was made to treat with percutaneous coronary intervention (pci) * patients will be eligible for the study whether they were undergoing primary pci. * signed written informed consent exclusion criteria: * patients with cardiac arrest, ventricular fibrillation, cardiogenic shock, stent thrombosis, previous acute myocardial infarction, or angina within 48 hours before infarction were not included in the study * patients with evidence of coronary collaterals (2-3 rentrop) to the region at risk on initial coronary angiography (at the time of admission) will be excluded * the patient has impaired renal function (creatinine \> 3.0 mg/dl) * the patient has known allergies to aspirin, clopidogrel bisulfate and ticlopidine, heparin, contrast media or stainless steel that cannot be managed medically * the patient needs therapy with warfarin * the patient has a life expectancy less than 12 months * recipient of heart transplant * the patient is currently participating in an investigational drug or another device study

Keywords: percutaneous coronary intervention vitamin c biomarkers magnetic risonance
safety and efficacy of adding intravenous n-acetyl cysteine in colon surgeries

Conditions: Systemic Inflammatory Response Syndrome

Summary: the use of antioxidant agents in the prevention or decreasing the severity of postoperative systemic inflammatory response syndrome after colonic surgeries adopted nowadays. therefore, it is of interest to investigate safety and efficacy of administrating short term intravenous (iv) n acetyl cysteine as add on to l alany l glutamine and total parenteral nutrition on the marker of oxidative stress malondialdehyde and anti- inflammatory marker tumor necrosis factor alpha in patients undergoing colonic surgeries through a prospective, randomized, double blinded, controlled clinical trial

a prospective, randomized, double blinded, controlled clinical trial will be carried out on 60 patients, who will admit to the critical care unit, ain shams hospitals, cairo, egypt, following colon surgeries. before the start of the study, eligible patients were randomized using computer generated list in order to allocate participants to either group i (n acetyl cysteine group) or group ii (control group) in an equal manner no medication will take before the surgery and only oral fluids were allowed on the day before the operation. all eligible patients underwent bowel preparation with oral 1.745 g/ 30 ml magnesium citrate, and phosphate containing enema on the day before surgery. all patients received the general anesthesia with endotracheal intubation and muscle relaxant. data management and analysis were performed using the statistical package for social sciences (spss) software for windows version 18

Eligibility criteria:
inclusion criteria: * need for icu admission after colonic surgery * requirement of total parenteral nutrition for at least 5 days due to failure of or contraindication for enteral nutrition * signing a written informed consent. exclusion criteria: * patients with persistent hemodynamic instability (systolic blood pressure \<80 mm hg), renal impairment, hepatic insufficiency, severe or uncontrolled sepsis, persistent metabolic acidosis, head trauma,and heart failure * any sensitivity to components of l-alanyl l-glutamine (dipeptiven®, fresenius kabi, germany) or n acetyl cysteine
dose-finding, safety, and efficacy study of xvr011 added to standard of care in patients hospitalised for covid-19

Conditions: Covid19

Summary: this is a 2 part study where the first part (phase 1) evaluates the safety of xvr011 and aims to identify the recommended phase 2 dose. the second part (phase 2) follows after the part 1 and evaluates whether xvr011 added to standard of care in patients hospitalised for mild to moderate covid-19 is a safe, well tolerated, and effective treatment. part 1 (phase 1) is completed as per protocol. the sponsor does not intend to start part 2 (phase 2) due to change in company strategy for phase 2 design.


Eligibility criteria:
inclusion criteria: * is ≥ 18 years of age. * tested positive for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) by rt-pcr and/or antigen test. * had an onset of covid-19 symptom(s) within 8 days prior to screening; except for dyspnoea and/or tachypnoea for which an onset within 2 days prior to screening is applicable. * requires hospitalisation for medical care. * has oxygen saturation \>= 91%. exclusion criteria: * requires non-invasive or invasive mechanical ventilation and/or intensive care. * symptoms consistent with severe covid-19. * has received a monoclonal antibody, plasma from a person who recovered from covid-19 or any investigational treatment for covid-19 within 30 days prior to study treatment. * has received an investigational or approved vaccination against sars-cov-2 within 14 days prior to study treatment. note: other protocol defined inclusion/exclusion criteria apply
esketamine vs. ketorolac for prevention of postoperative pain and cognitive dysfunction after total knee arthroplasty

Conditions: Postoperative Pain; Postoperative Cognitive Dysfunction; Total Knee Arthroplasty

Summary: purpose: to compare esketamine and ketorolac separately and in combination to prevent postoperative pain and cognitive dysfunction after total knee arthroplasty

with the increase in human life span, orthopedic injuries and subsequent repair surgery have become a major health problem which impairs the life quality of patients and burdens healthcare systems worldwide. poor post-surgical pain control is a leading factor that hinders the physical rehabilitation and musculoskeletal functional recovery, and causes acute cognitive impairment and chronic pain syndrome. therefore, prophylaxis of postoperative pain is indispensable to postoperative comfort and satisfaction. there is no denying the fact that pathologic pain is related to central glutaminergic system and n-methyl-d-aspartate (nmda) receptor activation induced central sensitization. also, it is previously reported that neuroinflammation is associated with pain development and cognitive dysfunction. ketamine, a nmda receptor antagonist, is effective in reversing nmda receptor activation underlying pain states. but the side effects of ketamine limit its clinical application, such as gibberish and agitation. it is clarified that esketamine has lower side effects than ketamine and that antinociception of esketamine is stronger than ketamine. the following study is carried out to evaluate whether esketamine and ketorolac can prevent postoperative pain and cognitive impairment after total knee arthroplasty in patients.

Eligibility criteria:
inclusion criteria: 1. subject is scheduled to undergo total knee arthroplasty under a short general anesthesia of less than 2 hours 2. subject's american society of anesthesiologists physical status is i-ii. 3. the subject's parent/legally authorized guardian has given written informed consent to participate. exclusion criteria: 1. subject has a diagnosis of bronchial asthma, coronary heart disease, severe hypertension, renal failure or liver failure. 2. subject has a diagnosis of insulin dependent diabetes. 3. subject is allergy and contraindication to esketamine or ketorolac. 4. subject has a history of chronic pain, a history of alcohol or opioid abuse, pre- existing therapy with opioids. 5. subject has any contraindication for the use of patient-controlled analgesia (pca). 6. subject is pregnant or breast-feeding. 7. subject is obese (body mass index \>30kg/m\^2). 8. subject is incapacity to comprehend pain assessment and cognitive assessment.

Keywords: esketamine ketorolac
what factors are associated with prognosis of rotator cuff disorder after subacromial hyaluronic acid injection

Conditions: Rotator Cuff Impingement Syndrome

Summary: to evaluate the correlations between structure of supraspinatus tendon (impingement, tendinopathy or partial tear, as well as full thickness tear) on ultrasonography and its response to subacromial hyaluronic acid injection in rotator cuff disease patients

objective: to evaluate the correlations between structure of supraspinatus tendon (impingement, tendinopathy or partial tear, as well as full thickness tear) on ultrasonography and its response to subacromial hyaluronic acid injection in rotator cuff disease patients and also investigate the factors associated with clinically important improvement after subdeltoid hyaluronic acid for rotator cuff disorder. design: prospective, longitudinal comparison study. participants: patients with rotator cuff disease intervention: three subacromial injection with hyaluronic acid with 2 week-interval. main outcome measures: visual analog scale (vas) of the shoulder pain, constant score, spadi score, and angles of active shoulder range of motion (flexion, abduction, external rotation, and internal rotation) at pre-treatment, post-treatment at week 4 and post-treatment at week 12.

Eligibility criteria:
inclusion criteria were patients 1. with clinically and ultrasonographically diagnosed rotator cuff disease of the shoulder-impingement, tendinosis and tear; 2. who reported shoulder pain more than 3 months; exclusion criteria: 1. presence of another medical or psychological condition, including cancer, rheumatoid arthritis, endocrine disease (i.e., diabetes), major depression, or schizophrenia; 2. previous major trauma history at currently affected shoulder; 3 primary osteoarthritis of the glenohumeral joint in a simple radiograph; 4previous injection history at the affected shoulder within 3 months

Keywords: rotator cuff disorder
ascorbyl peroxide association with bronchopulmonary dysplasia

Conditions: Bronchopulmonary Dysplasia

Summary: urinary ascorbyl peroxide level in the first week of life will be a good predictor of bronchopulmonary dysplasia (bpd) in preterm infants less than 33 weeks of gestation.

this study uses ascorbyl peroxide as representative of oxidative stress in premature infants on parenteral nutrition and aims to test the correlation of this metabolite and the different major neonatal outcomes 'mainly bronchopulmonary dysplasia).

Eligibility criteria:
inclusion criteria: * preterm infants less than 33 weeks of gestation\< * admission to chu sainte-justien neonatal intensive care unit * receiving parenteral nutrition during the first week of life * parental consent exclusion criteria: * major congenital anomalies * sever perinatal asphyxia

Keywords: ascorbyl peroxide bronchopulmonary dysplasia redox status necrotising entercolitis retinopathy of prematurity patent ductus arteriosus intraventricular hemorrhage periventricular leucomalacia
phenylketonuria and hyperphenylalaninemia nutrition study

Conditions: Phenylketonuria (PKU) and Hyperphenylalaninemia

Summary: the mainstay of pku treatment is a low-phenylalanine diet (i.e restriction of natural protein), and supplementation with a protein substitute (a mixture of amino acids free from phenylalanine, also containing micronutrients and vitamins) and special low-protein foods, to meet the patient's energy requirements. when diet and treatment is relaxed after childhood, adult and adolescent patients with phenylketonuria are at risk for malnutrition, depending on the compliance with treatment and the intake of amino acid supplements. in this study, nutrition status of patients with pku and hyperphenylalaninemia is systematically assessed under ongoing current treatment, in relation to phe-tolerance, compliance with treatment, and psychosocial issues. study participants do not undergo any specific therapeutic or diagnostic intervention.


Eligibility criteria:
inclusion criteria: * pku (phenylketonuria) or hyperphenylalaninemia * male or female, minimum age 16y * signed informed consent exclusion criteria: - patient who can not comply with the study protocol (e.g. unable to fill in questionnaires by themselves or a representative)
measuring renuvion soft tissue contraction using ultrasound

Conditions: Skin Laxity

Summary: this is a prospective, single-center, non-randomized study of up to 5 subjects who are receiving treatment with the renuvion apr system following power-assisted liposuction in the abdomen per investigator standard of care. ultrasound images of soft tissue contraction will be taken on abdomen prior to and during the procedure. measurements of contraction will be calculated from the ultrasound images by an ultrasonographer. all adverse events and expected treatment effects will be documented. follow-up photographs and ultrasound images will be captured at d30, d45, d60, d90, d180, d270, \& d365.

this is a prospective, single-center, non-randomized study of up to 5 subjects who are receiving treatment with the renuvion apr system following power-assisted liposuction in the abdomen per investigator standard of care. subjects may also have other body areas treated at the same time. demographic information, medical history, and procedure details will be documented. pre- and post-procedure care are per investigator standard of care and documented. video may be taken during the procedure. ultrasound images of soft tissue contraction will be taken on abdomen prior to and during the procedure. measurements of contraction will be calculated from the ultrasound images by an ultrasonographer. at baseline, photographs will be taken of the treatment areas. surface area measurements will be taken of each treatment area prior to study treatment. post-procedure care will be as per investigator standard of care and documented. all adverse events and expected treatment effects will be documented. follow-up photographs and ultrasound images will be captured at d30, d45, d60, d90, d180, d270, \& d365.

Eligibility criteria:
inclusion criteria: * patients who are scheduled for a procedure involving the use of renuvion for the contraction of subcutaneous soft tissue. patients undergoing procedures involving renuvion alone and/or renuvion following liposuction will be included. * patients who have acceptable cardiopulmonary health for outpatient surgery. * willing and able to comply with protocol requirements, including obtaining study-required images/photos and assessments, and returning for follow-up visits. * willing to release rights for the use of study photos, including in potential publication. * able to communicate with the site via video and/or photographs, in the event of a virtual follow-up visit. * able to read, understand, sign and date the informed consent document (english only). exclusion criteria: * bmi of greater than 35. * diabetes mellitus with a1c score \>7. * active cigarette smokers or nicotine vape users. * history of connective tissue disease (ehlers danlos, cutis laxa, pseudoxanthoma elasticum, marfan's, etc.) * patients who, in the opinion of the investigator, is not an appropriate candidate for the study. * patients requiring a concomitant procedure in the renuvion treatment area that could impact the ultrasound measurements or the effectiveness results.

Keywords: renuvion helium plasma
longitudinal advanced prostate cancer cohort (lapcc)

Conditions: Prostate Carcinoma

Summary: this study examines information from patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). by collecting biological samples (like blood, urine, and tissue), and health information (such as treatment, diet, and quality of life) researchers hope to learn more about prostate cancer and ways to improve outcomes in the future.

primary objective: i. to create an annotated biorepository with prospectively collected blood and urine samples from men with advanced prostate cancer. outline: this is an observational study. patients undergo blood and urine sample collection, complete surveys, and have their medical records reviewed on study.

Eligibility criteria:
inclusion criteria: * \* men of all racial and ethnic groups 18 years of age or older * men with a diagnosis of advanced (metastatic) prostate cancer who are scheduled to begin a new systemic treatment (including first or subsequent lines of therapy) * prior participation on clinical trials is allowed exclusion criteria: * \* inability to give informed consent
screening for depression and anxiety in patients with heart disease

Conditions: Depression; Depressive Symptoms; Depressive Disorder; Anxiety; Anxiety Disorders; Panic Attacks; Heart Diseases; Collaboration

Summary: depression is a risk factor for morbidity and mortality in patients with heart disease, and has a negative impact on quality of life, work capacity and treatment adherence. screening for depression among heart patients are therefore recommended by the norwegian health authorities. also, symptoms of anxiety may negatively affect rehabilitation due to e.g. fear of physical activity and excessive worry. patients currently receiving treatment for heart disease at diakonhjemmet hospital will be screened for symptoms of depression and anxiety. if such symptoms are detected, patients will be offered a counselling session with a clinical psychologist. further, routines for collaborative communication between clinical psychologist, cardiologist and the patient's general physician will be emphasized.


Eligibility criteria:
inclusion criteria: * men and women over 18 years under treatment for myocardial infarction, heart failure, tachyarrhythmia and/or valvular heart disease at the department of internal medicine, diakonhjemmet hospital. exclusion criteria: * unable to provide informed consent. * unable to read and/or understand norwegian. * unable to complete a survey.

Keywords: depression anxiety panic attacks collaborative care heart disease and depression heart disease and anxiety heart disease and panic attacks